These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30303964)

  • 21. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
    Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
    Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML).
    Dunna NR; Rajappa S; Digumarti R; Vure S; Kagita S; Damineni S; Rao VR; Yadav SK; Ravuri RR; Satti V
    Asian Pac J Cancer Prev; 2010; 11(6):1811-6. PubMed ID: 21338238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
    Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
    Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
    Elrhman HAEA; El-Meligui YM; Elalawi SM
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
    Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
    Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
    Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic utility of six mutated genes for older patients with acute myeloid leukemia.
    Wang J; Ma Z; Wang Q; Guo Q; Huang J; Yu W; Wang H; Huang J; Washington Shao Y; Chen S; Jin J
    Int J Cancer; 2018 Apr; 142(8):1664-1670. PubMed ID: 29193057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.
    Tan AY; Westerman DA; Carney DA; Seymour JF; Juneja S; Dobrovic A
    J Hematol Oncol; 2008 Jul; 1():10. PubMed ID: 18664261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia.
    Wang S; Zhang YX; Huang T; Sui JN; Lu J; Chen XJ; Wang KK; Xi XD; Li JM; Huang JY; Chen B
    Int J Lab Hematol; 2018 Aug; 40(4):408-418. PubMed ID: 29573577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype.
    Ibáñez M; Such E; Onecha E; Gómez-Seguí I; Liquori A; Sellés J; Hervás-Marín D; Barragán E; Ayala R; LLop M; López-Pavía M; Rapado I; Neef A; Sanjuan-Pla A; Sargas C; Gonzalez-Romero E; Boluda-Navarro M; Andreu R; Senent L; Montesinos P; Martínez-López J; Angel Sanz M; Sanz G; Cervera J
    Sci Rep; 2020 Apr; 10(1):5904. PubMed ID: 32246042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia.
    Niavarani A; Horswell S; Sadri R; Bonnet D
    Ann Hematol; 2016 Jan; 95(2):179-90. PubMed ID: 26499507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
    Thiede C; Koch S; Creutzig E; Steudel C; Illmer T; Schaich M; Ehninger G
    Blood; 2006 May; 107(10):4011-20. PubMed ID: 16455956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.